Pharmacoepidemiological study of the dynamics of consumption of antihistamines in Ukraine
DOI:
https://doi.org/10.24959/cphj.15.1345Keywords:
antihistamines, AH treatment, ATC/DDD-methodology, allergic rhinitis, National Drug FormularyAbstract
According to the WHO, now allergy takes the 3rd place by the morbidity rate among other nosologies. According to statistics, 20-40% of the world population suffers from one or the other form of allergic diseases, and in Ukraine approximately 1.5% of the population has been diagnosed with allergy. However, the actual figures are much higher – up to 25% (about 10 million people). The aim of this study was to determine dynamics of AH consumption in Ukraine for three years and conduct the analysis of AH at the market for 2012 – 2014, as well as analysis of availability of drugs included into the standard of allergic rhinitis treatment, in the National Drug Formulary. The data from the National Drug Formulary of Ukraine (the 6th edition) and from the Appendix to the Order of the Ministry of Public Health No. 507 dated 28-12-2002 “Standards of medical care in allergic rhinitis” were used to determine availability of drugs included into the standard of AR treatment. The ATC/DDD methodology and data on the volume of AH consumption of Morion research and retrieval system “Medicines” were used to determine the volume of AH consumption. Currently, 14 INN AH, on the basis of which 164 drugs are proposed by TN, are presented in Ukraine. As of the end of 2014, Loratadine (2.62) > Levocetirizine (1.91) > Cetirizine (1.78) > Mebhydrolin (1.38) became the leading medicines among AH by the volume of consumption in the DDDs/1000/d indicator. The medicines included into the Appendix to the Order of the Ministry of Public Health No. 507 dated 28-12-2002 do not comply with current standards of treatment according to the guidelines of the World Allergy Organization; it indicates the preconditions of change in the Ukrainian recommendations for AR treatment in the near future.
References
Вивчення споживання лікарських засобів за анатомо-терапевтично-хімічною класифікацією та встановленими добовими дозами (ATC/DDD- методологія). Методичні рекомендації /А.М.Морозов, Л.В.Яковлєва, А.В.Степаненко та інш. – К.:Укрпатентінфо, 2013. – 32с.
Додаток до наказу МОЗ №507 від 28-12-2002 «Нормативи надання медичної допомоги при алергічному риніті»
Колесник М. (2014) Актуальные вопросы выявления и лечения аллергических заболеваний, Издательство «Морион», № 2 (100) – III/IV 2014 г.
Пухлик Б.М. (2004) Алергічні захворювання: навч. посібник. Нова книга, Вінниця, 240 с.
Пухлик Б.М. (2011) Аллергия — проблема не только аллергологов. Запорож. мед. журн., 13(2):108–110.
Федосова Т.Г., Ильина Н.И. (2005) Аллергические заболевания в клинической практике. РМЖ (Русский медицинский журнал), 13(15): 1022–1029.
Чекман І.С., Шумейко О.В., Тяжка О.В. (2004) Клініко-фармакологічні властивості протиалергічних препаратів. Ліки України, 1–2: 24–31
Introduction to drug utilization research // WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. //World Health Organization, 2003/ - 48 p.
Mucci T., Govindaraj S., Tversky J. (2011) Allergic rhinitis. Mt. Sinai J. Med., 78(5): 634–644.
Rewiew of the use defined daily dose concept in drug utilization research in China//Lida Teng, Hua-wen Xin, Hege Salvesen Blix//Pharmacoepidemiology and drug safety. – 2012 – Wiley Online Library. – 10.1002 [Электронный ресурс]. – Режим доступа к сайту http://www.f.u-tokio.ac.jp/-utdpm/paper2/2012_Lida Review.pdf
Simons F.E., Simons K.J. (2011) Histamine and H1-antihistamines: celebrating a century of progress. J. Allergy Clin. Immunol., 128(6): 1139–1150
World Allergy Organization – 2010 – [Элетронный ресурс] Режим доступа к сайту: http://www.worldallergy.org/
Downloads
Published
Issue
Section
License
Copyright (c) 2015 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
